LAMP3 and neoplasm: IHC analyses on pre-treatment tumor biopsies highlighted that patient who developed DCB tended to have higher immune infiltration characterized by higher percentage of PDL1+ tumor cells, and higher densities of CD3+ T cells, FOXP3+ cells and DCLAMP+ dendritic cells than patients without DCB after treatment (Fig. 3C).